• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Spinal and Paraspinal Plexiform Neurofibromas in Patients with Neurofibromatosis Type 1: A Novel Scoring System for Radiological-Clinical Correlation.脊髓和脊柱旁丛状神经纤维瘤在神经纤维瘤病 1 型患者中的表现:一种用于放射-临床相关性的新的评分系统。
AJNR Am J Neuroradiol. 2017 Oct;38(10):1869-1875. doi: 10.3174/ajnr.A5338. Epub 2017 Aug 10.
2
Surgical Management of "Kissing" Spinal Plexiform Neurofibromas in Neurofibromatosis Type 1 Patients.1 型神经纤维瘤病患者“亲吻”型脊柱丛状神经纤维瘤的外科治疗。
World Neurosurg. 2020 Feb;134:e1143-e1147. doi: 10.1016/j.wneu.2019.11.124. Epub 2019 Nov 28.
3
Myeloneuropathy due to multiple giant plexiform neurofibromas - an unusual presentation of neurofibromatosis type 1.多发性巨大丛状神经纤维瘤所致脊髓神经病——1型神经纤维瘤病的一种罕见表现
BMJ Case Rep. 2017 May 6;2017:bcr-2017-220092. doi: 10.1136/bcr-2017-220092.
4
Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report.患者患有 1 型神经纤维瘤病,臀部和膀胱巨大丛状神经纤维瘤:病例报告。
J Med Case Rep. 2024 Jan 13;18(1):15. doi: 10.1186/s13256-023-04315-z.
5
Mystery Case: Widespread plexiform neurofibromas in neurofibromatosis type 1: An uncommon cause of back pain.
Neurology. 2017 Oct 31;89(18):e218-e219. doi: 10.1212/WNL.0000000000004595.
6
Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.1 型神经纤维瘤病患者使用全身 MRI 进行的神经内神经纤维瘤生长行为的 10 年随访。
Neurology. 2023 Feb 14;100(7):e661-e670. doi: 10.1212/WNL.0000000000201535. Epub 2022 Nov 4.
7
Rare triad of periampullary carcinoid, duodenal gastrointestinal stromal tumor and plexiform neurofibroma at hepatic hilum in neurofibromatosis type 1: a case report.1型神经纤维瘤病患者出现壶腹周围类癌、十二指肠胃肠道间质瘤和肝门部丛状神经纤维瘤的罕见三联征:一例报告
BMC Cancer. 2017 Aug 29;17(1):579. doi: 10.1186/s12885-017-3567-z.
8
Plexiform neurofibroma of uterus: a rare manifestation of neurofibromatosis 1.子宫丛状神经纤维瘤:神经纤维瘤病1型的一种罕见表现。
J Coll Physicians Surg Pak. 2014 Mar;24 Suppl 1:S22-3.
9
Is a plexiform neurofibroma pathognomonic of neurofibromatosis type I?丛状神经纤维瘤是I型神经纤维瘤病的特征性表现吗?
Laryngoscope. 2004 Aug;114(8):1410-4. doi: 10.1097/00005537-200408000-00018.
10
The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.妊娠对 1 型神经纤维瘤病中神经纤维瘤生长动力学的影响。
PLoS One. 2020 Apr 28;15(4):e0232031. doi: 10.1371/journal.pone.0232031. eCollection 2020.

引用本文的文献

1
Current state of spinal nerve sheath tumor management and future advances.脊神经鞘瘤治疗的现状与未来进展
Neurooncol Adv. 2024 Jul 17;6(Suppl 3):iii83-iii93. doi: 10.1093/noajnl/vdae067. eCollection 2024 Oct.
2
A Translational Approach to Spinal Neurofibromatosis: Clinical and Molecular Insights from a Wide Italian Cohort.脊髓神经纤维瘤病的转化研究方法:来自意大利广泛队列的临床与分子见解
Cancers (Basel). 2022 Dec 22;15(1):59. doi: 10.3390/cancers15010059.
3
Cutaneous Findings in Neurofibromatosis Type 1.1型神经纤维瘤病的皮肤表现
Cancers (Basel). 2021 Jan 26;13(3):463. doi: 10.3390/cancers13030463.
4
The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.MEK抑制剂司美替尼可减轻1型神经纤维瘤病(NF1)和丛状神经纤维瘤患者的脊髓神经纤维瘤负担。
Neurooncol Adv. 2020 Aug 8;2(1):vdaa095. doi: 10.1093/noajnl/vdaa095. eCollection 2020 Jan-Dec.
5
Spinal manifestations of Neurofibromatosis type 1.1型神经纤维瘤病的脊柱表现
Childs Nerv Syst. 2020 Oct;36(10):2401-2408. doi: 10.1007/s00381-020-04754-9. Epub 2020 Jun 20.

本文引用的文献

1
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.司美替尼在1型神经纤维瘤病相关丛状神经纤维瘤中的活性
N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.
2
Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.聚乙二醇化干扰素α-2b治疗1型神经纤维瘤病年轻患者及不可切除丛状神经纤维瘤的II期试验。
Neuro Oncol. 2017 Feb 1;19(2):289-297. doi: 10.1093/neuonc/now158.
3
Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.苹果酸舒尼替尼用于治疗丛状神经纤维瘤的临床前证据。
Pediatr Blood Cancer. 2016 Feb;63(2):206-13. doi: 10.1002/pbc.25763. Epub 2015 Sep 16.
4
Incidence and mortality of neurofibromatosis: a total population study in Finland.神经纤维瘤病的发病率和死亡率:芬兰的一项全人群研究。
J Invest Dermatol. 2015 Mar;135(3):904-906. doi: 10.1038/jid.2014.465. Epub 2014 Oct 29.
5
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.西罗莫司治疗进展性1型神经纤维瘤病相关丛状神经纤维瘤:神经纤维瘤病临床试验联盟II期研究
Neuro Oncol. 2015 Apr;17(4):596-603. doi: 10.1093/neuonc/nou235. Epub 2014 Oct 14.
6
Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging.一项自然史研究中,使用磁共振成像对1型神经纤维瘤病儿童和成人的脊柱检查结果进行特征描述。
J Neurooncol. 2015 Jan;121(1):209-15. doi: 10.1007/s11060-014-1629-5. Epub 2014 Oct 8.
7
The natural history of spinal neurofibromatosis: a critical review of clinical and genetic features.脊柱神经纤维瘤病的自然病史:对临床和遗传特征的批判性综述
Clin Genet. 2015 May;87(5):401-10. doi: 10.1111/cge.12498. Epub 2014 Nov 22.
8
Diagnosis, treatment and survival of 65 patients with malignant peripheral nerve sheath tumors.诊断、治疗和 65 例恶性外周神经鞘瘤患者的生存情况。
Anticancer Res. 2014 Feb;34(2):777-83.
9
Musculoskeletal manifestations of neurofibromatosis type 1.神经纤维瘤病 1 型的肌肉骨骼表现。
AJR Am J Roentgenol. 2012 Jul;199(1):W99-106. doi: 10.2214/AJR.11.7811.
10
Surgical management of cervical spine manifestations of neurofibromatosis Type 1: long-term clinical and radiological follow-up in 22 cases.神经纤维瘤病 1 型颈椎表现的手术治疗:22 例的长期临床和影像学随访。
J Neurosurg Spine. 2011 Mar;14(3):356-66. doi: 10.3171/2010.9.SPINE09242. Epub 2011 Jan 14.

脊髓和脊柱旁丛状神经纤维瘤在神经纤维瘤病 1 型患者中的表现:一种用于放射-临床相关性的新的评分系统。

Spinal and Paraspinal Plexiform Neurofibromas in Patients with Neurofibromatosis Type 1: A Novel Scoring System for Radiological-Clinical Correlation.

机构信息

From the Gilbert Israeli NF Center (M.M.-H., B.S., S.B.-S., L.B.-S., S.C., F.B.).

Pediatric Radiology Unit (M.M.-H., L.B.-S.).

出版信息

AJNR Am J Neuroradiol. 2017 Oct;38(10):1869-1875. doi: 10.3174/ajnr.A5338. Epub 2017 Aug 10.

DOI:10.3174/ajnr.A5338
PMID:28798215
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7963632/
Abstract

BACKGROUND AND PURPOSE

Neurofibromatosis type 1 is a common tumor predisposition syndrome. The aim of this study was to characterize the radiologic presentation of patients with neurofibromatosis type 1 with widespread spinal disease and to correlate it to clinical presentation and outcome.

MATERIALS AND METHODS

We conducted a historical cohort study of adult patients with neurofibromatosis type 1 with spinal involvement. Longitudinal clinical evaluation included pain and neurologic deficits. Radiologically, spinal involvement was classified according to a novel classification system, and a radiologic risk score was calculated.

RESULTS

Two hundred fifty-seven adult patients with neurofibromatosis type 1 are followed in our center. Thirty-four of these patients qualified for inclusion in this study. Three independent factors were found to be associated with increased risk for neurologic deficit: 1) bilateral tumors at the same level in the cervical region that approximated each other, 2) paraspinal tumors at the lumbar region, and 3) intradural lesions. On the basis of these factors, we calculated a combined risk score for neurologic deficits for each patient. We found a clear correlation between patient status and the calculated radiologic risk score. Patients with neurologic deficits were found to have a higher risk score (9 ± 8.3) than patients without neurologic deficits (2.5 ± 2.9, < .05). Patients who progressed during the follow-up period had significantly higher scores at presentation than patients with stable conditions (9.9 ± 8.73 versus 3.9 ± 5.3, respectively; < .05).

CONCLUSIONS

In this series, neurologic deficit is correlated with tumor burden and subtype. We found no direct correlation with tumor burden and pain. Our novel radiologic classification scoring system may be used to predict increased risk for neurologic morbidity.

摘要

背景与目的

神经纤维瘤病 1 型是一种常见的肿瘤易感性综合征。本研究的目的是描述广泛脊柱疾病的神经纤维瘤病 1 型患者的放射学表现,并将其与临床表现和结果相关联。

材料与方法

我们对患有脊柱受累的神经纤维瘤病 1 型成年患者进行了历史性队列研究。纵向临床评估包括疼痛和神经功能缺损。放射学上,根据一种新的分类系统对脊柱受累进行分类,并计算放射学风险评分。

结果

我们中心对 257 例神经纤维瘤病 1 型成年患者进行了随访。其中 34 例符合纳入本研究的标准。发现 3 个独立因素与神经功能缺损风险增加相关:1)颈椎同一水平双侧且相互接近的肿瘤,2)腰椎旁肿瘤,3)硬膜内病变。基于这些因素,我们为每位患者计算了神经功能缺损的综合风险评分。我们发现患者的状态与计算出的放射学风险评分之间存在明显的相关性。有神经功能缺损的患者的风险评分(9±8.3)明显高于无神经功能缺损的患者(2.5±2.9,<0.05)。在随访期间进展的患者的评分明显高于病情稳定的患者(9.9±8.73 与 3.9±5.3,分别;<0.05)。

结论

在本系列中,神经功能缺损与肿瘤负担和亚型相关。我们没有发现与肿瘤负担和疼痛之间的直接相关性。我们新的放射学分类评分系统可用于预测神经功能障碍的风险增加。